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adherence to treatment for type 2 diabetes
in an urban area of Bangladesh: protocol for a
randomized controlled trial
Sheikh Mohammed Shariful Islam1,2*, Andreas Lechner3, Uta Ferrari3, Guenter Froeschl2, Dewan Shamsul Alam1,
Rolf Holle4, Jochen Seissler3 and Louis W Niessen5Abstract
Background: Mobile phone technologies including SMS (short message service) have been used to improve the
delivery of health services in many countries. However, data on the effects of mobile health technology on patient
outcomes in resource-limited settings are limited. The aim of this study therefore is to measure the impact of a mobile
phone SMS service on treatment success of newly diagnosed type 2 diabetes in an urban area of Bangladesh.
Methods/design: This is a single-centred randomized controlled intervention trial (prospective) comparing
standard-of-care with standard-of-care plus a mobile phone-based SMS intervention for 6 months. A total of
216 participants with newly diagnosed type 2 diabetes will be recruited. Data will be collected at the outpatient
department of Bangladesh Institute of Health Science (BIHS) hospital at baseline and after 6 months. The primary
outcome measure will be change in HbA1c between baseline and 6 months. The secondary outcome measures
are self-reported medication adherence, clinic attendance, self-reported adoption of healthy behaviours, diabetes
knowledge, quality of life and cost effectiveness of the SMS intervention. The inclusion criteria will be as follows:
diagnosed as patients with type 2 diabetes by the BIHS physician, using oral medication therapy, living in Dhaka city,
registered with the BIHS hospital, using a mobile phone, willing to return for follow up after 6 months and providing
written informed consent. Participants will be allocated to control and intervention arms after recruitment using a
randomization software. Data will be collected on socio-demographic and economic information, mobile phone
use and habits, knowledge of prevention, management and complications of diabetes, self-perceived quality of life
assessment, self-reported diseases, medical history, family history of diseases, medication history, medication adherence,
health seeking behaviour, tobacco use, physical activity, diet, mental health status, life events and disability,
anthropometric measurements of weight, height, blood pressure and blood tests for HbA1c.
Discussion: Mobile phone SMS services have the potential to communicate with diabetes patients and to
build awareness about the disease, improve self-management and avoid complications also in resource-limited
setting. If this intervention proves to be efficient and cost-effective in the current trial, large-scale implementation could
be undertaken.
Trial registration: DRKS00005188.* Correspondence: shariful.islam@icddrb.org
1Center for Control of Chronic Diseases, International Center for Diarrhoeal
Diseases Research, Bangladesh (ICDDR,B), 68, Shaheed Tajuddin Ahmed
Sarani, Mohakhali, Dhaka 1212, Bangladesh
2Center for International Health (CIH), Ludwig-Maximilians-Universität (LMU),
Leopoldstrasse 7, 80802 Munich, Germany
Full list of author information is available at the end of the article
© 2014 Islam et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Islam et al. BMC Health Services Research 2014, 14:586 Page 2 of 9
http://www.biomedcentral.com/1472-6963/14/586Background
Diabetes mellitus, particularly type 2, is one of the most
significant public health challenges of the 21st century.
More than 80% of diabetes related deaths occur in devel-
oping countries [1]. It is estimated that about 8.4 million
people living in Bangladesh are suffering from diabetes
already and by 2030, that number is expected to double,
placing Bangladesh among the top five countries in
terms of the absolute number of people living with
diabetes [2]. Population data support an increasing trend
in diabetes prevalence in Bangladesh, especially in urban
areas where the prevalence is 8.1% compared to 2.3% in
rural areas [3].
Non-adherence rates for therapies of chronic illness
and for lifestyle changes are high with estimates ranging
from 36% to 93% and averaging only 50% in developed
countries [4,5]. Lack of adherence often leads to in-
creased use of healthcare services, poor quality of life
and increased healthcare costs [6,7]. In Bangladesh,
adherence to medication is low due to several complex
issues along with poor clinic attendance. This often
leads to insufficient glycaemic control and avoidable life
threatening complications. A recent study among newly
diagnosed type 2 diabetes in Bangladesh reported 84% of
patients had average to poor basic knowledge about their
disease [8].
Mobile phone interventions for health are an emer-
ging, rapidly-evolving practice and have been used to
improve delivery of health services in many countries of
the world [9]. Mobile phones can be a low cost solution
to provide health education and increase adherence to
treatment for people with chronic diseases like diabetes
[10]. A study using mobile phone SMS by nurses in
Korea found that SMS for 6 months reduced HbA1C in
diabetic patients to 1.15% at 3 months and 1.05% at
6 months compared with baseline in the intervention
group [11]. Mobile phone SMS have been shown to be
an effective tool for providing diabetes health education,
clinic and appointment reminders, medication reminders
and for building awareness about the disease [12-14].
However, no data on the effects of such an approach on
patient outcomes in resource-limited settings are avail-
able to date.
Research objectives
The objectives of this study are to:1) Study the effect of
mobile phone SMS on medication adherence and con-
trol of newly-diagnosed type 2 diabetes in an urban area
of Bangladesh; 2) Test the use of mobile phone SMS as
clinic appointment reminders and for building awareness
about diabetes and its complications; 3) Measure the im-
pact of mobile phone SMS on quality of life of diabetes
patients in Bangladesh and 4) Evaluate the cost effective-
ness of a mobile phone SMS intervention.The results of the study will help the policy-makers to
understand the importance of creating healthcare sys-
tems that better meets the needs of people and develop
prevention and management strategies for diabetes and
other chronic disease using innovative mobile phone
technologies at the national level which can be repli-
cated in other developing countries as well.
Hypothesis
Our primary hypothesis is that mobile phone SMS
intervention is superior in reducing HbA1c in newly
diagnosed type 2 diabetes compared to standard care.
Secondary hypothesis is mobile phone SMS will increase
diabetes knowledge, medication adherence and clinic at-
tendance better in the interventions group than in the con-
trol group. The third hypothesis is participants in the
mobile phone SMS group will have a better quality of life
than participants in the control group. The fourth hypoth-
esis is that mobile phone SMS will be a cost-effective
measure for glycaemic control.
Methods/Design
Study site and population
This study will be implemented at a Bangladesh Insti-
tute of Health Sciences (BIHS) Hospital Out Patient
Department (OPD) in Mirpur, Dhaka city which is
an affiliate organization of Diabetic Association of
Bangladesh (DAB). The total number of diabetic pa-
tients receiving services from the BIHS Hospital OPD
from July 2010 to June 2011 was 90,146 with 2026 new
registrations and total 693251 tests performed in the
laboratory of the Department of Biochemistry. The
average number of patients per day in the BIHS OPD
will be sufficient to cover the total sample size of this
study in a short period of time. We will limit our data
collection to this single center where the participants
represent urban areas of Dhaka and Bangladesh.
Consecutive patients from this center who meet the
eligibility criteria will be asked to participate in the
study.
Study type
We will conduct a randomized controlled trial , compar-
ing [1] standard-of- care (n = 108) with [2] standard-of-
care plus a mobile phone-based SMS intervention (n =
108) for 6 months among patients with newly diagnosed
type 2 diabetes receiving treatment at the OPD of BIHS
hospital in Dhaka City (Figure 1).
Sample size
Assuming that standard care with metformin reduces
HbA1c by 1% on average and the intervention adds an-
other 0,5% [15,16]. Assuming a SD of 1, which seems
reasonable and an alpha error level of 5%, the two-tailed
Flow Chart:   
Enrollment 
Allocation 
Follow-up 
after 6months 
Analysis  
Assessed for eligibility (n=300) 
Randomized (n=216) 
Excluded  (n=........) 
Not meeting inclusion criteria (n=...) 
Declined to participate (n=.....)
Allocated to intervention (n=108) Received 
allocated intervention (n=...) 
Did not receive allocated intervention 
(n=...) (give reasons)  
Allocated to control (n=108) 
Patients receive standard care only 
Analyzed  (n=90) Analyzed  (n=90) 
Lost to follow-up (n=...) (give reasons)  
Discontinued intervention (n=....)  
Lost to follow-up (n=...) (give reasons)  
Discontinued intervention (n=....)  
Figure 1 Flow chart. Flow chart of study participants in the trial.
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ticipants in each arm of the study. Considering 20% loss
of follow up by 6 months total sample size required for
this study will be 216.
Inclusion criteria:
 Diagnosed as type 2 diabetic patient according to
WHO criteria
 Currently on oral Metformin monotherapy and able
to afford cost for 6 months treatment
 Patients with a personal mobile phone
 Patients who know how to retrieve/read SMS on
mobile phone (Bangla with English alphabets)
 Willingness to receive SMS for 6 months at least
one SMS per day.
 Patient registered with the BIHS health centre and
lives in Dhaka City.
 Provide written informed consent and agree for a
follow up visit after 6 months. (SMS reminders will
be sent for the follow up visit).
Exclusion criteria:
 Patients with other types of diabetes, such as
diagnosed as type 1 diabetes, gestational diabetes.
 Patients whose clinical condition might have
interfered with the study such as mental illness,
other serious illness or co-morbidities requiring
hospitalization.
 Patients unable to give their informed consent or
agree for follow up visit.
 Patients who do not own a mobile phone or cannot
read SMS messages.
 Patients who reside outside Dhaka city.Randomization
All the study participants will be randomized to receive
either the standard care or mobile phone SMS interven-
tions plus standard care. A central computer generated
randomization list with patient ID numbers will be gen-
erated. Data collection and laboratory assays will be
done by investigators masked to intervention allocation;
however, study participants cannot be masked as they
will receive the SMS intervention (Figure 1).
Data collection and intervention
Data will be collected at baseline (0 month) and after
6 months through questionnaires, physical measure-
ments and blood tests (Figure 1). We will send out mo-
bile phone SMS to patients in the intervention group for
medication reminders and health education about dia-
betes, its complications, diet and physical activity. SMS
content has been developed using different national and
international guidelines for diabetes and will be field
tested for clarity and contents. The patients will be en-
couraged to send messages/call the study team for any
queries encountered in response to the text messages.
The study team will then call patients who had a prob-
lem within 2 working days. Study staff will maintain a
study register to record all SMS responses and other
mobile phone communications with patients in a study
log.
SMS development and testing
The SMS messages were developed by a team compris-
ing of general physicians, an endocrinologist, an epi-
demiologist, a nurse and a undergraduate student. After
developing the SMS messages in Bengali, we sent these
messages to several individuals in the pre-test stage
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formal education qualifications. After receiving the feed-
back, we tried to make the contents of the SMS suitable
for the general population. We will ensure that all our
participants in the study can read the SMS messages by
themselves or someone in the family who can describe
the messages to them if they do not understand. At the
end of the follow-up we will evaluate if they failed to
understand any of the SMS.
Most of the 90 SMS were developed based on the prin-
ciples of behavioural learning theory and transtheoretical
model of behavioural change [17-19]. All participants in
the SMS intervention group will receive the 90 SMS ran-
domly, once a day over the 6 months period. Some exam-
ples of the SMS are provided below:
 Diabetes is a serious disease, but it can be easily
controlled
 Check your blood pressure at least for 2 times in a
year and write it down
 Regular physical exercise or walking habit will help
to bring your blood glucose to normal level
 Don't forget to take your medication as advised by
your physician
 A planned diet and weight control will help to
reduce the risk of heart disease and stroke
 Do you have any appointment with your doctor in
this month? Then do not miss it.
 Have you done your physical activity, walking for
30 minutes or exercise today? If not then do it when
you become free
 If you are stressed, stop your work. Go for a walk
and relax!
 A healthy diet will keep you healthy and happy
 Did you take all your medication today as advised by
your physician?
 Visiting your doctor timely is essential for you
 Discuss with your doctor about your concerns and
worries about your condition
 Awareness about your disease and following your
doctor's advice can make your life healthy and
happy
 Taking medication timely will help to keep your
blood sugar in control and avoid complications
 Diabetic people with disciplined life enjoys a healthy
longer life.
We will attempt to replicate interview and physical
measurements in a random sub-set (~5%) of the sample
to evaluate repeatability. For repeatability studies, we will
have about 40 participants with duplicate measures
which will be sufficient to estimate kappa coefficients of
agreement of inter and intra-observer reliability with a
high degree of precision even for categorical variables.Quality monitoring and assurance
Data collection forms will be checked on a daily basis by
a Research Fellow to ensure complete and accurate data
entry by field staff. Cross checking of data collection
forms will be performed in the field by the data collec-
tors for inconsistency and missing data. The Principal
Investigator (PI) will carry out periodic data checks and
look for systematic patterns, errors, scheduling problems
or incomplete forms. Every week when the team meets,
the PI will pick 2 questionnaires filled in the current
week by one interviewer. The PI will go through the
questionnaire, question by question with the entire team,
to identify incomplete/missing entries and any errors as
to rectify and clear any doubts by the interviewers.
Primary outcome measures
[Time Frame: 6 months]
 Disease progression (HbA1c level).
The primary analysis will be intention to treat which
will provide relative unbiased comparisons among the
intervention and control groups. It will also reduce the
effects of crossover and dropout, which may break the
random assignment to the treatment groups in a study.
Secondary outcome measures
[Time Frame: 6 months]
 Diabetes knowledge (questionnaire)
 Self-reported medication adherence (Questionnaires)
 Clinic attendance (Clinic registers and
questionnaires)
 Quality of Life (Self-reported questionnaires)
 Cost effectiveness of SMS interventions in reducing
HbA1c
Description of outcome variables:
 Socio-demographic and economic information: Data
on participant’s age, sex, religion, education, marital
status, occupation, income, family size, family
income, objects owned
 Mobile phone use and habits: Owns mobile phone,
years of using mobile phone, can read SMS, can
send SMS, frequency of sending SMS, monthly
expenses for mobile phone and SMS, willingness to
pay for SMS health advice/ medication reminder,
maximum amount for mHealth
 Knowledge of prevention, management and
complications of diabetes: Levels of knowledge and
perceptions of diabetics, Risk Factors for diabetes,
knowledge about prevention, management and
complications of diabetes.
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use EQ-5D tool and other modified tools to assess
the Quality of Life for all participants. This
questionnaire has been tested and validated to
capture the difference in quality of life in chronic
diseases patients.
 Self-reported diseases or disease prevalence:
Self -reported information on different diseases
and physical disability by the study participants.
 Medical History: Any known history of diabetics,
CVD, hypertension, cancer, hypercholesterolemia,
stroke, kidney diseases, other vascular disease, major
surgery.
 Family history of diseases: Family history of diabetes,
hypertension, heart diseases, stroke, kidney diseases,
cancer
 Medication history: List of current and past
medication taken by the patient, medication for
diabetes, average monthly expenditure for
medication, transportation to health facility/
physician and consultation.
 Medication adherence: We will data on medication
adherence of participants using different
standardized tools and modifying to local context.
 Health seeking behaviour: Data will be collected on
type of doctor visited during the past year, number
of visits, distance travelled for consultation and
expenditure for health.
 Tobacco Use (WHO modified questionnaire): A
modified WHO questionnaire on use of different
forms of tobacco currently and in the past with
expenditure will be recorded.
 Physical Activity (GPAQ): WHO modified GPAQ
questionnaire which has been validated in the fields
will be used to capture information on different
forms of physical activity
 Diet (WHO IMS/ Food Frequency Questionnaire):
A modified and validated food frequency
questionnaire will be administrated to ascertain food
consumption pattern and dietary choices, type and
frequency of consumption of different foods.
 Mental health status (PHQ9): The Patient Health
Questionnaire PHQ 9 which is a standard tool for
collecting mental health status in primary health
care setting will be used.
 Life events and Disability: Life events related
questions like new job, marriage, separation, injury,
accident will be asked, which will be based on
validated questionnaire.
 Anthropometric Measurements: Weight, Height,
Mid-Upper Arm Circumference (MUAC), Waist and
Hip circumference, Blood Pressure (BP), Pulse rate.
 Biological tests: Blood tests for HBA1C will be
performed.A standard operating procedure (SOP) will be devel-
oped for questionnaire administration, physical measure-
ment, SMS, biological sample collection, transport and
storage. Medical history and family history will be ob-
tained through a face-to-face interview using structured
questionnaire. The medication use will be recorded from
patient's medication book that is maintained by all
registered patients. The duration of diabetes, duration of
hypertension and complications will be collected from
patient medical records maintained by BIHS physician,
review of the patient’s file and investigations.
Data analysis
Data coding, quality control and data entry will be done
following established procedures at the International
Center for Diarrhoeal Diseases Research, Bangladesh
(icddr, b). Precoded questionnaire will be used to
minimize data coding errors. All data forms and ques-
tionnaires will be checked for errors and necessary cor-
rections will be made before data entry. A data entry
programme with built-in range and consistency checks
will be used. Frequency distributions will be run to iden-
tify outliers. In all analyses, potential confounding vari-
ables and effect modifiers will be considered.
Basic presentations of data will include number and
percentages of cases with diabetes by age, sex, location
of residence, and in relation to different known risk fac-
tors. Chi-square tests will be used to assess the associ-
ation between diabetes and risk factors. Prevalence odd
ratios will be calculated for diabetes adjusted for major
confounding variables (e.g. age, sex, smoking habits, so-
cioeconomic status, nutritional status, family history of
diabetes). Interaction between age and risk factors, obes-
ity and diabetes risk factors, and nutritional status and
risk factor (hypertension and diabetes risk factors) will
also be examined in the logistic regression model.
Effect of intensive mobile phone SMS intervention will
be examined by comparing the longitudinal change in
glycated hemoglobin (HbA1c) level changes between
intervention and control groups. The change in HbA1C
will be defined as the difference between mean HbA1c
at the first survey and minus that at the second survey
and standardized for the time between surveys. We will
analyze the primary outcomes with the t-test. The primary
analysis will be intention to treat which will provide rela-
tive unbiased comparisons among the intervention and
control groups. It will also reduce the effects of crossover
and dropout, which may break the random assignment to
the treatment groups in a study. Relative risk (RR) will be
reported for non-adherence, with an RR less than 1 sug-
gesting better outcome for the intervention group. As a
measure of absolute effect size, we will also calculate the
number needed to treat (NNT) and its associated 95% CI
for both unadjusted primary outcomes. Adjusted analyses
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comes with adjustments for sex, age, baseline HbA1c level
will be performed.
Secondary outcomes will be compared with the χ2 test
for categorical outcome. Fisher's exact test for outcomes
will be used to estimate p values. Logistic regression will
be used for Quality of Life (QoL) and other continuous
variables. In the subgroup analysis in the intention-to-
treat population, we will compare the intervention
groups within each subgroup of patients with the χ2 test
for the categorical outcome and logistic regression for
QoL. For all models, the results are expressed as an esti-
mate of effect size, with 95% CIs and p values. The
response type throughout the study period will be ana-
lysed by categorising time since random allocation to
the 6 months and doing a χ2 test between time and re-
sponse type. All statistical analyses will be done using
SPSS version 20 (IBM Corporation, USA).
Health economic analysis
Primary analyses: We will measure the economic impact
of the mobile phone based SMS interventions. All rele-
vant costs incurred during the observation period will be
assessed and compared between the two study arms.
Cost for the intervention excluding the costs caused by
the study will be considered. To calculate the economic
cost of intervention we will use the CostIt (Costing
Interventions templates) tool developed by WHO. The
CostIt tool provides a set of separate templates for the
reporting and analysis of costs at the programme, hos-
pital, primary health facility and household levels. The
following steps will be used:
1. Define the costs (identify all direct and indirect
costs)
2. Evaluate the total cost of SMS intervention
The data collection tools have been designed to cap-
ture cost measurement for medication, transportation,
consultation, blood tests, days lost due to illness,
hospitalization costs and other associated direct and in-
direct costs. Costs associated with mobile phone SMS
interventions will be recorded in a separate register and
used for data analysis in measuring the costs which
includes costs for personnel, materials and supplies, op-
erating costs, maintenance costs, utilities, capital costs
and other indirect costs. Cost for standard of care, costs
for the SMS intervention and accessing the SMS inter-
vention will be calculated. Also, costs associated with
productivity gained due to improvement of health condi-
tions will be assumed.
In order to estimate the impact of mobile phone SMS
on diabetes control, we will conduct a within-trial cost-
effectiveness analysis which examines cost associatedwith health gains. The measure of effect will be units of
HbA1C reduction. In addition, a cost effectiveness-analysis
will be conducted where health gains are expressed in
terms of health-related quality of life as measured by the
EQ-5D questionnaire. The within-trial cost effectiveness
analysis will be performed with support Prof. Rolf Holle
and his team at the Institute of Health Economics and
Health Care Management of the Helmholtz Zentrum
Muenchen, Germany.
Ethics
All participants will be explained about the objectives,
importance, risks and benefits of the research before
recruitment. Participation will be completely voluntary
and an appropriate written informed consent will be ob-
tained from all participants. All participants will be given a
copy of the consent form and contact details of the study
coordinator for their future questions and concerns. All
participants will have access to send SMS or call the study
team for advice and suggestions during the study period
as a compensation for participating in the study.
All participants will be assigned a unique alpha-
numeric subject ID. All data-set, biological samples and
clinical investigations performed for the study will be
identified by the unique subject ID given to each partici-
pant. Staff at the laboratory will not have access to the
confidential codes linking the subject IDs to the personal
identifier. The hard-copies of all the data collection
forms will be stored and locked at icddr, b and access to
these files will only be given to the PI’s, and authorized
staff. All computer databases will be protected by
firewalls and a password-entry system. Only PI and des-
ignated staff will have access to database and files
matching personal identifiers to subject IDs for the pur-
poses of contacting study participants for follow-up.
Publications and scientific presentations of the findings
from the study will be presented in aggregates and iden-
tity of individual participants will be kept confidential.
Local health authority in the study site will be in-
formed of the study and discussions will be held about
management of any clinical problems arising during the
study. Any participant who is discovered to have a
chronic disease or risk factor(s) that require manage-
ment will be appropriately informed about the condition
and its implications by a medical member of the study
team. They will then be referred to an appropriate ser-
vice for further management.
This study has been approved by icddr, b Research Re-
view Committee (PR# 13018) on 15 April, 2013 and Eth-
ical Review Committee on 28th May 2013.
Discussion
This article describes the protocol for a randomized con-
trol study to measure the effects of mobile phone SMS
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tendance and glycemic control for patients with type 2
diabetes in an urban area of Bangladesh. This study is
the first in developing countries, to the best of our
knowledge, to measure the impacts of mobile phone
SMS for diabetes. One of the most significant barriers to
effective treatment of type 2 diabetes is a lack of aware-
ness and education about diabetes, its complications and
optimal way to treatment which can be addressed by
mobile phone interventions for knowledge generation,
awareness and behaviour change communications.
Although a nationally representative and multi-center,
cluster randomized controlled trial is optimum from the
methodological perspective for this study, due to lack of
resources and time constraints we have to limit our study
to a single centre. However, data gathered from this study
will allow us to evaluate the effectiveness and cost-
effectiveness of SMS interventions in reducing HbA1c
from within the trial. In recent years there are numerous
attempts to integrate mobile phones for health inter-
ventions and this study can direct future research in
Bangladesh for diabetes management in clinical set-
tings using innovative mobile technologies.
Participants will be identified before randomization in
an attempt to avoid bias. We will initially inform the
participants about the study and after obtaining in-
formed consent will conduct the interviews and obtain
blood samples for HbA1c. We will then randomize the
participants using a random allocation software to the
intervention and control arms.
Using SMS as tools for medication and appointment
reminders; disseminate health information and life-style
messages are easy technology that can be applied by per-
sons with minimum technical knowledge and skills. In
this study, we will send the SMS to participants using a
internet modem with build-in software for sending SMS
and bulk messages. As the SMS will be written in
Bengali using English alphabets we assume it will not be
very difficult for participants to read and understand.
However, as the literacy rate of Bangladesh has been re-
ported to be only 62.5%, the ability to read the SMS mes-
sages were considered in the inclusion criteria which does
not automatically translate into the ability to understand
the contents of the SMS.
Outcomes between the two groups will be measured
after 6 months by standardised questionnaires, review of
medical records and patient medication book, physical
measurements and biological sample to determine ef-
fects of the intervention on outcomes. Although the
short time period will not allow us to evaluate the im-
pact of mobile phone SMS on development of diabetic
complications, this will provide us with a baseline data
which can be tested on future extension of this study.
Furthermore, we expect that the SMS will have someimpact on lifestyle outcome measures than on metabolic
parameters because a lifestyle change must occur before
we can measure an effect on metabolic parameters. We
expect the metabolic parameters to have stronger long-
term effects. Also, it is expected that the SMS interven-
tion will possibly help to increase knowledge about
diabetes and its complications, leading to better medica-
tion adherence which ultimately might lead to better
glycaemic control.
Although we originally intended to perform detailed
health economic analysis for this study we considered
that secondary analyses will be performed depending on
positive results of the primary analyses and the availabil-
ity of human resources. In the secondary analyses, we
will attempt to combine the short-term evidence from
the SMS intervention study with expected long-term ef-
fects and outcomes for the patients. These analyses will
use decision-analytic models such as Markov or state
transition models to describe the disease process.
Each unit of HbA1c reduction will be converted to
a health outcome unit for example DALY (Disability
Adjusted Life Years) gained and compared between non-
intervention and intervention in terms of financial unit.
The DALY extends the concept of potential years of life
lost due to premature death (PYLL) to include equiva-
lent years of “healthy” life lost by virtue of being in states
other than good health. DALYs lost due to diabetes will
be calculated as the sum of the years of life lost due to
premature mortality (YLL) in the population and the
equivalent “healthy” years lost due to non-fatal health
conditions (YLD) : DALY = YLL + YLD.
When measuring the burden of diabetes, or the decre-
ment in health due to diabetes, each year of life lost is
given a weight of 1. Years lived, but in states less than
full health, are given a weight between 0 and 1, with 0
representing full health. Using standardized population
models such as WHO developed PopMod [20], we will
calculate the benefits of the SMS intervention compared
to standard of care. The outcome will be measured in
terms of costs and effects. For both the standard of care
and SMS intervention we will measure the expected
costs and expected outcomes and the results expressed
as ratio of difference in expected costs and effects.
SMS for health promotion have been well-accepted by
beneficiaries and may be an effective tool for providing
diabetes health education, clinic and appointment re-
minders, medication reminders and building awareness
about the disease [12-14]. A recent study in Netherlands
showed that SMS reminders improved adherence of type
2 diabetes patients, especially the precision with which
the patients followed their prescribed regimen and that
it was well accepted by the patients [21]. Numerous
issues must be considered when designing and implement-
ing client-centered programs, including mobile phone
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and technological challenges. More information is needed
about best practices for developing content for text message
delivery and the optimal timing of messages [22].
Abbreviations
SMS (Short Message Service): SMS is a way to send short messages using an
alphabet, numbers, and symbols. SMS messages are digital information that
can be transmitted over mobile networks, without Internet signal.; mHealt
(Mobile Health): “the use of mobile computing and communication
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